VYNE Therapeutics Inc.
VYNE
$0.36
-$0.01-2.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 39.67% | -65.15% | 106.12% | 10.53% | 6.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.67% | -65.15% | 106.12% | 10.53% | 6.14% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 39.67% | -65.15% | 106.12% | 10.53% | 6.14% |
| SG&A Expenses | -8.74% | -16.97% | -13.13% | -18.40% | -2.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.74% | -28.16% | 25.69% | 86.07% | 108.13% |
| Operating Income | 40.48% | 27.45% | -24.62% | -86.91% | -109.99% |
| Income Before Tax | 38.92% | 38.83% | -37.85% | -95.22% | -100.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 38.92% | 38.83% | -37.85% | -95.29% | -100.25% |
| Earnings from Discontinued Operations | -- | 27.27% | 0.00% | 77.78% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.12% | 38.82% | -37.80% | -94.28% | -84.64% |
| EBIT | 40.48% | 27.45% | -24.62% | -86.91% | -109.99% |
| EBITDA | -- | -- | -- | -87.39% | -- |
| EPS Basic | 40.42% | 39.07% | -37.47% | -39.29% | 85.77% |
| Normalized Basic EPS | 39.24% | 25.31% | -37.55% | -43.37% | 84.57% |
| EPS Diluted | 40.42% | 39.07% | -37.47% | -39.29% | 85.77% |
| Normalized Diluted EPS | 39.24% | 25.31% | -37.55% | -43.37% | 84.57% |
| Average Basic Shares Outstanding | 0.50% | 0.41% | 0.22% | 36.18% | 1,197.59% |
| Average Diluted Shares Outstanding | 0.50% | 0.41% | 0.22% | 36.18% | 1,197.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |